The DOI matches its Crossref record.
Privileged Structures: Applications in Drug Discovery
Abstract
Over the past 15 years the privileged structure concept has emerged as a fruitful approach to the discovery of novel biologically active molecules. Privileged structures are molecular scaffolds with versatile binding properties, such that a single scaffold is able to provide potent and selective ligands for a range of different biological targets through modification of functional groups. In addition, privileged structures typically exhibit good drug-like properties, which in turn leads to more drug-like compound libraries and leads. The net result is the production of high quality leads that provide a solid foundation for further development. The identification of privileged structures will be discussed, emphasizing the importance of understanding the structure-target relationships that confer "privileged" status. This understanding allows privileged structure based libraries to be targeted at distinct target families (e.g. GPCRs, LGIC, enzymes/kinases). Privileged structures have been successfully exploited across and within different target families and promises to be an effective approach to the discovery and optimization of novel bioactive molecules. The application of the privileged structure approach, both in traditional medicinal chemistry and in the design of focused libraries, will be discussed with the aid of illustrative examples.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cited by
Lead- and drug-like compounds: the rule-of-five revolution
Lipinski, C. A. (2004) · Drug Discovery Today: Technologies · doi:10.1016/j.ddtec.2004.11.007 · Cited by 6,199
Privileged scaffolds for library design and drug discovery
Welsch, M. E., Snyder, S. A., & Stockwell, B. R. (2010) · Current Opinion in Chemical Biology · doi:10.1016/j.cbpa.2010.02.018 · Cited by 1,509
“Intriguingly, most of the structures identified were re-occurring elements in biologically active compounds already known and considered as privileged before the study [6 ].”
BackgroundChalcone: A Privileged Structure in Medicinal Chemistry
Zhuang, C., Zhang, W., Sheng, C., Zhang, W., Xing, C., & Miao, Z. (2017) · Chemical Reviews · doi:10.1021/acs.chemrev.7b00020 · Cited by 1,463
Galloway, W. R. J. D., Isidro-Llobet, A., & Spring, D. R. (2010) · Nature Communications · doi:10.1038/ncomms1081 · Cited by 891
Keri, R. S., Patil, M. R., Patil, S. A., & Budagumpi, S. (2015) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2014.10.059 · Cited by 631
Diversity-oriented synthesis: Exploring the intersections between chemistry and biology
Tan, D. S. (2005) · Nature Chemical Biology · doi:10.1038/nchembio0705-74 · Cited by 605
Bioactive Benzofuran derivatives: A review
Khanam, H., & Shamsuzzaman (2015) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2014.11.039 · Cited by 554
Singh, M. S., & Chowdhury, S. (2012) · RSC Advances · doi:10.1039/c2ra01056a · Cited by 506
Khan, I., Ibrar, A., Abbas, N., & Saeed, A. (2014) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2014.02.005 · Cited by 469
Ruthenium-Catalyzed Azide Alkyne Cycloaddition Reaction: Scope, Mechanism, and Applications
Johansson, J. R., Beke-Somfai, T., Said Stålsmeden, A., & Kann, N. (2016) · Chemical Reviews · doi:10.1021/acs.chemrev.6b00466 · Cited by 414
Chemical substructures that enrich for biological activity
Klekota, J., & Roth, F. P. (2008) · Bioinformatics · doi:10.1093/bioinformatics/btn479 · Cited by 392
“Our analysis also revealed ‘underprivileged’ substructures and ‘conditional privilege’—rules relating combinations of substructure to bioactivity.”
BackgroundGaba, M., & Mohan, C. (2016) · Medicinal Chemistry Research · doi:10.1007/s00044-015-1495-5 · Cited by 366
Drug repurposing from an academic perspective
Oprea, T. I., Bauman, J. E., Bologa, C. G., Buranda, T., Chigaev, A., Edwards, B. S., Jarvik, J. W., Gresham, H. D., Haynes, M. K., Hjelle, B., et al. (2011) · Drug Discovery Today: Therapeutic Strategies · doi:10.1016/j.ddstr.2011.10.002 · Cited by 364
Understanding cancer and the anticancer activities of naphthoquinones – a review
Wellington, K. W. (2015) · RSC Advances · doi:10.1039/c4ra13547d · Cited by 316
HIV‐1 NNRTIs: structural diversity, pharmacophore similarity, and impliations for drug design
Zhan, P., Chen, X., Li, D., Fang, Z., De Clercq, E., & Liu, X. (2013) · Medicinal Research Reviews · doi:10.1002/med.20241 · Cited by 192
Metadata
- Authors
- DeSimone, R., Currie, K., Mitchell, S., Darrow, J., & Pippin, D.
- Venue
- Combinatorial Chemistry & High Throughput Screening
- Publisher
- Bentham Science Publishers Ltd.
- Published
- 2004-08-01
- Volume
- 7
- Issue
- 5
- Pages
- 473-493
- ISSN
- 1386-2073 (ISSN-L)
- OpenAlex
- W2111986931
- Cited by
- 577
- References
- 0
- FWCI
- 12.58
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.